New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Gilead Sciences, Inc.

GILD

Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.

Revenue
+6.83%
EPS
−20.2%
Free cash flow
+21.1%
Total debt
+5.17%

Quarter to September 2026, against a year earlier

168.69 2.16 +1.30%
Market cap
$207.8B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
1.95%
F-score
8/9
ROIC
−4.51%
Net debt / EBITDA
1.4×
Payout ratio
—

Gilead Sciences, Inc. (GILD) EV/Sales

Alert me on EV/Sales

As of Nov 19, 2026, Gilead Sciences, Inc. (GILD) trades at a EV/Sales of 7.3×. Over the past ten years it has ranged from 3.3× (June 2017) to 7.6× (November 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 4.1× and above the Healthcare sector median of 3.3×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 5.8× 25.86%
FY2024 4.6× 1.22%
FY2023 4.5× (2.79%)
FY2022 4.7× 13.31%
FY2021 4.1× 3.20%
FY2020 4.0× 6.84%
FY2019 3.7× 3.92%
FY2018 3.6× (11.08%)
FY2017 4.0× 6.96%
FY2016 3.8× (20.99%)

Quarterly newest first

Period EV/Sales Change
Sep 2026 6.6× 11.82%
Jun 2026 5.9× (6.28%)
Mar 2026 6.3× 9.29%
Dec 2025 5.8× 7.95%
43 more quarters

Against its own ten years

Low 3.3× High 7.6×
Ten-year median 4.2×
Current reading's percentile 99

EV/Sales against peers

Company EV/Sales
SNY Sanofi compare 2.1×
BMY Bristol Myers Squibb Company compare 3.0×
PFE Pfizer Inc. compare 3.2×
NVO Novo Nordisk A/S compare 3.6×
AZN AstraZeneca PLC compare 4.7×
MRK Merck & Co., Inc. compare 5.5×
NVS Novartis AG compare 5.6×
AMGN Amgen Inc. compare 7.2×
GILD Gilead Sciences, Inc. 7.3×
Drug Manufacturers General industry median 4.1×
Healthcare sector median 3.3×
Market median 2.0×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on GILD